Prestige Consumer Healthcare (PBH) Change in Accured Expenses (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Change in Accured Expenses came in at $2.4 million in Q4 2025, down 35.5% year-on-year from $3.8 million in Q4 2024, and down 48.59% quarter-over-quarter from $4.7 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $2.4 million for Q4 2025.
- On a quarterly basis, Change in Accured Expenses fell 35.5% year-over-year to $2.4 million in Q4 2025; TTM through Dec 2025 was $9.0 million, a 317.72% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 143.07% from the prior year.
- Change in Accured Expenses eased to $2.4 million in Q4 2025 per PBH's latest filing, from $4.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $18.4 million in Q2 2021 and bottomed at -$23.1 million in Q1 2021.
- The 5-year median for Change in Accured Expenses is $830500.0 (2022), against an average of -$283250.0.
- Across the five-year window, Change in Accured Expenses jumped 379.42% in 2023 and plunged 453.98% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at -$9.5 million in 2021, then soared by 84.84% to -$1.4 million in 2022, then soared by 379.42% to $4.0 million in 2023, then fell by 6.37% to $3.8 million in 2024, then sank by 35.5% to $2.4 million in 2025.
- Per Business Quant, the three latest PBH Change in Accured Expenses figures stand at $2.4 million (Q4 2025), $4.7 million (Q3 2025), and -$813000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Prestige Consumer Healthcare | 2.41 Bn | 2.35 Bn | 157.37 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.44 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | -813,000.00 |
| Jun 30, 2025 | -813,000.00 |
| Mar 31, 2025 | 2.63 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 3.78 Mn |
| Dec 31, 2024 | 3.78 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -2.06 Mn |
| Mar 31, 2024 | -8.49 Mn |
| Mar 31, 2024 | -8.49 Mn |
| Dec 31, 2023 | 4.03 Mn |
| Dec 31, 2023 | 4.03 Mn |
| Sep 30, 2023 | -3.25 Mn |
| Sep 30, 2023 | -3.25 Mn |